First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study
Head & Neck · 2025
DOI: 10.1002/hed.28211 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Head & Neck, 2025. Verfasst von Alizée Simon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Neoplasm Recurrence, Local, Antibodies, Monoclonal, Humanized, Head and Neck Neoplasms. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
In Europe, pembrolizumab with or without chemotherapy is the recommended first‐line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with a combined positive score (CPS) ≥ 1. In France, the TPExtreme (TPEx) regimen is preferred for CPS < 1. These regimens were studied in selected populations, which may not reflect real‐world patients.
Methods
We reviewed all R/M HNSCC cases treated with first‐line regimens between January 2021 and December 2023 in Nancy and Lille. Data on patient history, treatments, survival, response, and safety were collected. PFS and OS were analyzed using the Cox multivariable regression model, adjusting for the covariates age, Eastern Cooperative Oncology Group (ECOG) performance status, comorbidities, and nutritional status.
Results
The analysis included 290 patients; 19% received pembrolizumab alone, 28% received pembrolizumab with chemotherapy, 19% received TPEx, and 20% received adapted regimens. PFS and OS differed significantly between groups. Median PFS and OS were respectively 2.9 and 9.4 months for pembrolizumab, 6 and 15.5 months for pembrolizumab‐chemotherapy, 5.9 and 13.7 months for TPEx, and 4.3 and 10 months for adapted regimens. Pembrolizumab alone is the safest regimen.
Conclusion
This retrospective study reflects real‐world first‐line therapy for R/M HNSCC in two French cancer institutes. Pembrolizumab combined with chemotherapy is the preferred treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France.
- Faculté de médecine de Nancy, Université de Lorraine, Nancy, France.
- Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
- Department of ENT - Head and Neck Surgery, Centre Hospitalier Regional Universitaire de Nancy, Nancy, France.
- Department of Radiation Oncology, Institut de Cancérologie de Lorraine, Nancy, France.
ORCID-Profile: Alizée Simon
Zitieren
APA
Simon, A., Abdeddaim, C., Nguyen, D., Gallet, P., Peiffert, D., Lambert, A., & Geoffrois, L. (2025). First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study. Head & Neck. https://doi.org/10.1002/hed.28211
Vancouver
Simon A, Abdeddaim C, Nguyen D, Gallet P, Peiffert D, Lambert A, et al. First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study. Head & Neck. 2025. doi:10.1002/hed.28211
BibTeX
@article{Simon2025,
author = {Simon, Alizée and Abdeddaim, Cyril and Nguyen, DucTrung and Gallet, Patrice and Peiffert, Didier and Lambert, Aurélien and Geoffrois, Lionnel},
title = {First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.28211}
}
EUVIMED